This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sirukumab

Johnson & Johnson

Drug Names(s): CNTO 136, anti-IL6 mAB, CNTO-136

Description: CNTO 136 is a fully human monoclonal antibody designed to inhibit the function of interleukin-6 (IL-6), a pro-inflammatory cytokine that stimulates an immune response to trauma and has been shown to play a role in multiple disease indications. By inhibiting IL-6, CNTO 136 is designed to reduce or prevent symptoms associated with autoimmunity and inflammation.

Deal Structure: Janssen and GlaxoSmithKline
In December 2011, GSK and Janssen Biologics (Ireland) entered into a co-development and co-commercialization license agreement with respect to sirukumab for RA.

Partners: GlaxoSmithKline plc


Sirukumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug